Stereotaxis Expands Robotic Surgery Portfolio with FDA Approvals and Robocath Acquisition
Event summary
- Stereotaxis received FDA approval for its MAGiC catheter in January 2026 and Synchrony digital OR system in April 2026.
- The company announced a definitive agreement to acquire Robocath, expanding its robotic surgery portfolio.
- Q1 2026 revenue was $6.3M, down from $7.5M in Q1 2025, with gross margin at 60%.
- Stereotaxis expects double-digit revenue growth for 2026, with annual revenue surpassing $40M.
The big picture
Stereotaxis is undergoing a strategic transformation, shifting from legacy technology to a new product ecosystem aimed at minimally invasive endovascular interventions. The acquisition of Robocath and recent FDA approvals position the company to compete in the growing robotic surgery market, but success hinges on its ability to scale manufacturing and integrate new technologies efficiently. The company's focus on disposable revenue per procedure marks a structural shift in its business model, potentially enhancing profitability.
What we're watching
- Regulatory Success
- The pace at which Stereotaxis can secure additional regulatory approvals for its new product ecosystem will determine its market expansion.
- Execution Risk
- How Stereotaxis manages the operational and commercial friction to ramp up manufacturing and implement new products will impact its revenue growth.
- Market Adoption
- Whether the demand for MAGiC catheters can be sustained and scaled beyond current supply constraints.
Related topics